Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2024

01-04-2024 | Pancreatic Cancer | Review Article

Role of interferon-induced transmembrane protein family in cancer progression: a special focus on pancreatic cancer

Authors: Peipei Wang, Yan Pan, Yu Zhang, Congliang Chen, Junmei Hu, Xia Wang

Published in: Medical Oncology | Issue 4/2024

Login to get access

Abstract

Human interferon-induced transmembrane protein family (IFITMs) consists of five main proteins. IFITM1, IFITM2, and IFITM3 can be induced by interferon, while IFITM5 and IFITM10 are insensitive to interferon. IFITMs has various functions, including well-researched antiviral effects. As a molecule whose expression is significantly increased by interferon in the immune microenvironment, IFITMs has drawn growing interest in recent years for their role in the cancer progression. Unlike antiviral effects, the role and mechanism of IFITMs in cancer progression have not been clearly studied, especially the role and molecular mechanism of IFITMs in pancreatic cancer are rarely reported in the literature. This article focuses on the role and potential mechanism of IFITMs in pancreatic cancer progression by analyzing the function and mechanism of IFITM1-3 in other cancers and conducting bioinformatics analysis using the databases, so as to provide a new target for pancreatic cancer therapy.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Lewin AR, et al. Molecular analysis of a human interferon-inducible gene family. Eur J Biochem. 1991;199:417–23.PubMedCrossRef
5.
Siegrist F, et al. The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res. 2011;31:183–97.PubMedCrossRef
6.
John SP, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013;87:7837–52.PubMedPubMedCentralCrossRef
7.
8.
9.
10.
Bozzo CP, et al. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat Commun. 2021;12:4584.CrossRef
11.
Gomez-Herranz M, et al. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. J Biol Chem. 2023;299: 102741.PubMedCrossRef
12.
Liu X, et al. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-beta signaling pathway. Cell Death Dis. 2019;10:517.PubMedPubMedCentralCrossRef
13.
Xu L, et al. IGF1/IGF1R/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 2017;393:76–85.PubMedCrossRef
14.
Hu J, et al. Mechanism and biological significance of the overexpression of IFITM3 in gastric cancer. Oncol Rep. 2014;32:2648–56.PubMedCrossRef
15.
Yu F, et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 2015;368:135–43.PubMedCrossRef
16.
17.
18.
Daniel-Carmi V, et al. The human 1–8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene. Int J Cancer. 2009;125:2810–9.PubMedCrossRef
19.
Andreu P, et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res. 2006;66:1949–55.PubMedCrossRef
20.
Yang N, et al. Predicative value of IFITM2 in renal clear cell carcinoma: IFITM2 is associated with lymphatic metastasis and poor clinical outcome. Biochem Biophys Res Commun. 2021;534:157–64.PubMedCrossRef
21.
Cai Y, et al. Interferon-induced transmembrane protein 3 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Front Immunol. 2021;12: 704965.PubMedPubMedCentralCrossRef
22.
Cui Y, et al. Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation. Biochem Biophys Res Commun. 2018;495:733–9.PubMedCrossRef
23.
Koh YW, et al. Prognostic significance of IFITM1 expression and correlation with microvessel density and epithelial-mesenchymal transition signature in lung adenocarcinoma. Pathol Res Pract. 2019;215: 152444.PubMedCrossRef
24.
Sakamoto S, et al. Interferon-induced transmembrane protein 1 (IFITM1) promotes distant metastasis of small cell lung cancer. Int J Mol Sci. 2020;21(14):4934.PubMedPubMedCentralCrossRef
25.
Lui AJ, et al. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21. Cancer Lett. 2017;399:29–43.PubMedPubMedCentralCrossRef
26.
Yang M, et al. Knockdown of interferon-induced transmembrane protein 3 expression suppresses breast cancer cell growth and colony formation and affects the cell cycle. Oncol Rep. 2013;30:171–8.PubMedCrossRef
27.
Hou Y, et al. Interferon-induced transmembrane protein 3 expression upregulation is involved in progression of hepatocellular carcinoma. Biomed Res Int. 2021;2021:5612138.PubMedPubMedCentralCrossRef
28.
Seyfried NT, et al. Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett. 2008;263:243–52.PubMedPubMedCentralCrossRef
29.
30.
Mizoshiri N, et al. The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma. Cell Oncol (Dordr). 2019;42:861–71.PubMedCrossRef
31.
Liu Y, et al. High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia. Cancer Gene Ther. 2020;27:38–44.PubMedCrossRef
32.
Liang Y, et al. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming. Mol Cancer. 2022;21:182.PubMedPubMedCentralCrossRef
33.
Akyerli CB, et al. Expression of IFITM1 in chronic myeloid leukemia patients. Leuk Res. 2005;29:283–6.PubMedCrossRef
34.
Carmelle R, et al. Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol Ther. 2006;5:1383–9.CrossRef
35.
Wu L, et al. Identification of IFN-induced transmembrane protein 1 with prognostic value in pancreatic cancer using network module-based analysis. Front Oncol. 2021;11: 626883.PubMedPubMedCentralCrossRef
36.
Lei Z, et al. Knockdown of interferon-induced transmembrane protein 1 inhibited proliferation, induced cell cycle arrest and apoptosis, and suppressed MAPK signaling pathway in pancreatic cancer cells. Biosci Biotechnol Biochem. 2020;84:1603–13.CrossRef
37.
Yang G, et al. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene. 2007;26:594–603.PubMedCrossRef
38.
Zhang Y, et al. Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in vitro. Exp Ther Med. 2020;19:755–61.PubMed
39.
Gan CP, et al. IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells. Cell Oncol (Dordr). 2019;42:477–90.PubMedCrossRef
40.
Liu Y, et al. Interferon-induced transmembrane protein 2 promotes epithelial–mesenchymal transition by activating transforming growth factor-beta1/small mother against decapentaplegic 2 signaling in gastric cancer. Mol Biol Rep. 2022;49:997–1006.PubMedCrossRef
41.
42.
Li Q, et al. RUNX1 promotes tumour metastasis by activating the Wnt/beta-catenin signalling pathway and EMT in colorectal cancer. J Exp Clin Cancer Res. 2019;38:334.PubMedPubMedCentralCrossRef
43.
Hatano H, et al. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 2008;14:6097–105.PubMedCrossRef
44.
He JD, et al. Influences of the interferon induced transmembrane protein 1 on the proliferation, invasion, and metastasis of the colorectal cancer SW480 cell lines. Chin Med J (Engl). 2012;125:517–22.PubMed
45.
46.
Weichselbaum RR, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008;105:18490–5.PubMedPubMedCentralCrossRef
47.
Khodarev NN, et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A. 2004;101:1714–9.PubMedPubMedCentralCrossRef
48.
Le TV, et al. Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res. 2010;33:1127–32.PubMedCrossRef
49.
Goad DW, et al. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Mol Ther Oncolytics. 2022;24:59–76.PubMedCrossRef
50.
Choi HJ, et al. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015;17:6.PubMedPubMedCentralCrossRef
51.
Salas S, et al. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. Int J Cancer. 2009;125:851–60.PubMedCrossRef
52.
Li H, et al. Expression and prognostic value of IFITM1 and IFITM3 in head and neck squamous cell carcinoma. Am J Clin Pathol. 2020;153:618–29.PubMedCrossRef
53.
Chan RH, et al. The expression quantitative trait loci in immune response genes impact the characteristics and survival of colorectal cancer. Diagnostics (Basel). 2022;12:315.PubMedCrossRef
54.
Peters BA, et al. The lung microbiome, peripheral gene expression, and recurrence-free survival after resection of stage II non-small cell lung cancer. Genome Med. 2022;14:121.PubMedPubMedCentralCrossRef
55.
56.
Popson SA, et al. Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis. Arterioscler Thromb Vasc Biol. 2014;34:1011–9.PubMedPubMedCentralCrossRef
57.
Murphy K, et al. Janeway’s immunobiology. 8th ed. New York: Garland Science; 2011. p. 685–7.
58.
59.
Thibaut R, et al. Bystander IFN-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat Cancer. 2020;1:302–14.PubMedPubMedCentralCrossRef
60.
Yang Y, et al. The interferon-inducible 9–27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett. 2005;221:191–200.PubMedCrossRef
61.
Vences-Catalan F, et al. Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res. 2015;75:4517–26.PubMedCrossRef
62.
Shen C, et al. Identification of differentially expressed transcripts targeted by the knockdown of endogenous IFITM3. Mol Med Rep. 2016;14:4367–73.PubMedCrossRef
63.
64.
Rosati A, et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat Commun. 2015;6:8695.PubMedCrossRef
65.
Yanez DC, et al. IFITM proteins drive type 2 T helper cell differentiation and exacerbate allergic airway inflammation. Eur J Immunol. 2019;49:66–78.PubMedCrossRef
66.
67.
68.
69.
Metadata
Title
Role of interferon-induced transmembrane protein family in cancer progression: a special focus on pancreatic cancer
Authors
Peipei Wang
Yan Pan
Yu Zhang
Congliang Chen
Junmei Hu
Xia Wang
Publication date
01-04-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02308-6

Other articles of this Issue 4/2024

Medical Oncology 4/2024 Go to the issue

Original Paper

Exploring the Potential of Essential Oil from Plectranthus amboinicus Leaves against Breast Cancer: In vitro and In silico Analysis

Original Paper

Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway

Review Article

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Original Paper

In vitro anticancer activity of Hirudinaria manillensis methanolic extract and its validation using in silico molecular docking approach

Original Paper

High expression of CD9 and Epidermal Growth Factor Receptor promotes the development of tongue cancer

Original Paper

An effective treatment approach of liposomally encapsulated metformin in colon cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits